What could cause elevated total testosterone with low free testosterone in a postmenopausal woman taking norethindrone?

Elevated Total Testosterone with Low Free Testosterone in a Postmenopausal Woman on Norethindrone

The most likely cause is norethindrone-induced elevation of sex hormone-binding globulin (SHBG), which increases total testosterone by reducing its clearance while simultaneously binding more testosterone and lowering the free (bioactive) fraction. Additionally, norethindrone directly interferes with certain testosterone immunoassays, particularly the Roche E170 system, causing falsely elevated total testosterone readings 1.

Primary Mechanisms

1. SHBG-Mediated Effect (Physiologic)

Norethindrone, despite being classified as an androgenic progestin, paradoxically increases SHBG levels when used as monotherapy or in combination with estrogen 2, 3. This creates a characteristic pattern:

• Elevated SHBG binds more circulating testosterone
• Total testosterone appears elevated because SHBG-bound testosterone has slower metabolic clearance
• Free testosterone decreases because more testosterone is protein-bound and unavailable for tissue uptake
• The bioactive portion of testosterone that enters tissues is reduced 4

This mechanism is well-established: SHBG levels are raised by estrogen and progestins, while being suppressed by androgens, insulin resistance, and hypothyroidism 4. In postmenopausal women on norethindrone, the progestin effect on SHBG dominates.

2. Laboratory Interference (Artifactual)

Norethindrone causes direct assay interference in testosterone immunoassays, particularly the Roche E170 Modular system, producing falsely elevated total testosterone readings exceeding 5 nmol/L (144 ng/dL) 1. This interference:

• Does not occur with liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods 1
• Shows smaller effects with Siemens ADVIA Centaur assays 1
• Can be unmasked by measuring testosterone via LC-MS/MS 5

Diagnostic Approach

Immediate Steps:

1. Verify the assay method used for testosterone measurement

   • If immunoassay (especially Roche): Repeat using LC-MS/MS to exclude interference 1
   • LC-MS/MS is the gold standard and unaffected by norethindrone 1

2. Measure SHBG levels simultaneously with testosterone

   • Calculate free testosterone using total testosterone and SHBG (most reliable method) 4
   • Direct free testosterone immunoassays are unreliable; computed values are preferred 4

3. Consider other causes of elevated SHBG in postmenopausal women:

   • Hypothyroidism (check TSH)
   • Liver disease
   • Genetic SHBG mutations (rare) 4

Clinical Context Matters:

• Absence of virilization signs (acne, hirsutism, clitoromegaly, voice deepening) makes true androgen excess unlikely 6
• Postmenopausal women normally have declining testosterone levels; mean total testosterone is approximately 25 ng/dL 7
• Very high testosterone (>150 ng/dL or adult male range) with rapid virilization warrants imaging for androgen-secreting tumor 4

Management Recommendations

If LC-MS/MS confirms truly elevated total testosterone with low free testosterone:

• This represents a benign pharmacologic effect of norethindrone on SHBG
• The low free testosterone is the clinically relevant value 4
• No intervention needed unless symptoms of androgen deficiency develop (low libido, fatigue)
• Continue norethindrone if indicated for its primary purpose (endometrial protection, bleeding control, etc.) 8

If LC-MS/MS shows normal total testosterone:

• The initial elevation was laboratory interference 1
• Document this in the medical record to prevent future confusion
• Use LC-MS/MS for all future testosterone measurements while on norethindrone

Key Pitfalls to Avoid

• Do not pursue extensive workup for androgen-secreting tumors based solely on elevated total testosterone in a woman on norethindrone without confirming results with LC-MS/MS 1, 5
• Do not use direct free testosterone immunoassays; they lack standardization and reliability 4
• Do not assume norethindrone has net androgenic effects systemically; it increases SHBG and decreases free testosterone despite theoretical androgenic properties 2, 3
• Remember that automated hospital immunoassays are often inadequate for measuring testosterone in women and require specialty laboratory validation 4

The combination of high total testosterone with low free testosterone in this clinical scenario is either an assay artifact or a predictable consequence of norethindrone's effect on SHBG—neither requires discontinuation of therapy or invasive investigation.